Gilead Sciences Inc (GILD)

64.29 -0.78  -1.20% NASDAQ Nov 18, 20:00 Delayed 2m USD
View Full Chart
Price Chart
View All Events

Events

Date Type Description
02/04/2020 16:30 EST Misc Gilead Sciences Inc Fourth Quarter Earnings Conference Call in 2019
02/04/2020 Earnings Gilead Sciences Inc Fourth Quarter Earnings in 2019 Release
12/12/2019 Dividends Amount: 0.63, Declared Date: Oct 24 2019, Pay Date: Dec 30 2019
10/24/2019 16:30 EDT Misc Gilead Sciences Inc Third Quarter Earnings Conference Call for 2019
10/24/2019 Earnings Gilead Sciences Inc Third Quarter Earnings in 2019 Release
09/12/2019 Dividends Amount: 0.63, Declared Date: Jul 30 2019, Pay Date: Sep 27 2019
07/30/2019 16:30 EDT Misc Gilead Sciences Inc Second Quarter Earnings Conference Call in 2019
07/30/2019 Earnings Gilead Sciences Inc Second Quarter Earnings in 2019 Release
06/13/2019 Dividends Amount: 0.63, Declared Date: May 02 2019, Pay Date: Jun 27 2019
05/08/2019 10:00 PDT Misc Gilead Sciences Inc Annual General Meeting in 2018
View All Performance Charts

Total Returns Comparison

Ratings & Reports

Advertisement
Edit

Profile

  • URL: http://www.gilead.com
  • Investor Relations URL: http://investors.gilead.com/phoenix.zhtml?c=69964&p=irol-irhome
  • HQ State/Province: California
  • Sector: Healthcare
  • Industry: Drug Manufacturers - General
  • Equity Style: Large Cap/Value
  • Next Earnings Release: Feb. 04, 2020
  • Last Earnings Release: Oct. 24, 2019
  • Next Ex-Dividend Date: Dec. 12, 2019
  • Last Ex-Dividend Date: Sep. 12, 2019
  • Description: Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite acquisition boosted Gilead's exposure to cell therapy in oncology.

Top Fund Holders

Symbol Name Weighting
IBB iShares Nasdaq Biotechnology ETF 7.54%
XLV Health Care Select Sector SPDR® ETF 2.26%
VHT Vanguard Health Care ETF 1.96%
RMEBX American Funds American Mutual R2E 1.68%
VLUE iShares Edge MSCI USA Value Factor ETF 1.51%
RAEFX American Funds AMCAP R5E 1.24%
RICHX American Funds Invmt Co of Amer R5E 1.19%
QQQ Invesco QQQ Trust 0.92%
RIREX American Funds Capital Income Bldr R4 0.77%
IVE iShares S&P 500 Value ETF 0.67%

Comparables

Edit
Advertisement

{{root.upsell.info.feature_headline}}.

{{root.upsell.info.feature_description}}

Please note that this feature is only available as an add-on to YCharts subscriptions.


Please note that this feature requires full activation of your account and is not permitted during the free trial period.

Start My Free Trial {{root.upsell.info.call_to_action}} No credit card required.

Already a subscriber? Sign in.